A new study from the Gray Faculty of Medical and Health Sciences at Tel Aviv University may mark a breakthrough in the ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

IonQ IONQ is rapidly positioning itself as a preferred partner for both commercial enterprises and government institutions ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

How could Trump's demands that drugmakers lower U.S. prices or face penalties impact pharma and biotech stocks? Seeking Alpha ...

So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific research and seems determined to scrap the research grants of Ivy League ...

Despite significant advances in early detection, surgery, radiotherapy, and systemic treatment of breast cancer, late relapse ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against ...

Meanwhile, drugmakers ramp up U.S. manufacturing investments to navigate policy shifts and protect supply chain resilience.